Login to Your Account



India: Now a Partner for Innovation

Sanofi Adds Glenmark Antibody to Portfolio for Potential $613M

By Catherine Shaffer


Tuesday, May 17, 2011
Glenmark Pharmaceuticals SA, a subsidiary of Glenmark Pharmaceuticals Ltd. India, based in Mumbai, licensed its monoclonal antibody GBR 500 to Paris-based Sanofi-Aventis SA for an up-front payment of $50 million, plus potential future milestone payments and double-digit royalties, for a total deal value up to $613 million. Glenmark said the deal is the largest of its kind from an emerging market, and is the first example of a novel biologic entity being licensed out of an emerging market.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription